A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

NCT06257966 on ClinicalTrials.gov · last registry update 2025-09-17

Closed to new participants; the 600 already enrolled are still being followed. Its estimated completion date, 1 October 2026, has passed with no update to the record. Primary outcome, as filed: HbA1c. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Beijing Dongfang Biotech Co., Ltd.
Sponsor type: Industry
Enrollment: 600
Started: 2024-07-17
Primary completion: 2026-10-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c

Conditions studied

Type2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.